Compare JD.Com Inc (JD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Repligen Corporation Common Stock — how do they compare? JD.Com Inc trades at $26.75 (market cap $36.93B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: JD.Com Inc is far larger — about 3.3× Repligen Corporation Common Stock's market cap, and JD.Com Inc pays a 3.75% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 86 Days and Repligen Corporation Common Stock for 0 Days on average.
| JD | RGEN | |
|---|---|---|
Market Cap | $36.93B | $11.31B |
Volume | 6,680,917 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $194.57 |
52-Week Low | $25.19 | $102.87 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $19.54B | $11.20B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.78, up 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.93 surpassing the $0.86 forecast. Revenue for 2025 reached $1.31 trillion, though net income margin compressed to 1.13%. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, which recently gained EU approval momentum (Reuters, 2026-10-02).
The stock appears undervalued with a P/E of 17.78 and P/S of 0.2, well below sector averages. Analyst consensus is strongly bullish with a $35.38 price target, implying ~32% upside. Key risks include regulatory scrutiny in China and Europe, volatile cash flows, and competitive pressures. The robust balance sheet with $234 billion cash provides a margin of safety, but investors must weigh growth initiatives against macroeconomic headwinds.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
